格雷斯治療公司
該符號不再有效

SecurityACST / Grace Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership4,548 shares
Latest Disclosed Value $ 21,057
Morgan Stanley reports 82.13% decrease in ownership of ACST / Grace Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 4,548 shares of Grace Therapeutics, Inc. (US:ACST) valued at $21,057 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 25,448 shares of Grace Therapeutics, Inc.. This represents a change in shares of -82.13% during the quarter. The current value of the position is $15,509 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F GRACE THERAPEUTICS COM 00439U104 4,548 -20,900 -82.13 21 -76.14 0.0000
2026-05-27 2025-12-31 13F/A-1 GRACE THERAPEUTICS COM 00439U104 25,448 23,600 1,277.06 88 1,660.00 0.0000
2026-02-13 2025-12-31 13F GRACE THERAPEUTICS COM 00439U104 25,448 23,600 88 0.0000
2026-05-27 2025-09-30 13F/A-1 GRACE THERAPEUTICS COM 00439U104 1,848 0 0.00 6 0.00 0.0000
2025-11-14 2025-09-30 13F GRACE THERAPEUTICS COM 00439U104 1,848 0 6 0.0000
2025-08-15 2025-06-30 13F GRACE THERAPEUTICS COM 00439U104 1,848 0 0.00 5 25.00 0.0000
2025-05-15 2025-03-31 13F GRACE THERAPEUTICS COM 00439U104 1,848 -34 -1.81 4 -42.86 0.0000
2025-05-15 2024-12-31 13F/A-1 GRACE THERAPEUTICS COM 00439U104 1,882 1,882 7 0.0000
2025-02-14 2024-12-31 13F GRACE THERAPEUTICS COM 00439U104 1,882 0 7 0.0000
2025-05-14 2024-09-30 13F/A-2 ACASTI PHARMA CL A 00430K865 1,882 0 0.00 6 0.00 0.0000
2025-02-14 2024-09-30 13F/A-1 ACASTI PHARMA CL A 00430K865 1,882 0 6 0.0000
2024-11-14 2024-09-30 13F ACASTI PHARMA CL A 00430K865 1,882 0 6 0.0000
2025-05-14 2024-06-30 13F/A-2 ACASTI PHARMA CL A 00430K865 1,882 0 0.00 5 -16.67 0.0000
2024-10-17 2024-06-30 13F/A-1 ACASTI PHARMA CL A 00430K865 1,882 0 5 0.0000
2024-08-14 2024-06-30 13F ACASTI PHARMA CL A 00430K865 1,882 0 5 0.0000
2024-10-17 2024-03-31 13F/A-2 ACASTI PHARMA CL A 00430K865 1,882 0 0.00 6 20.00 0.0000
2024-08-16 2024-03-31 13F/A-1 ACASTI PHARMA CL A 00430K865 1,882 0 6 0.0000
2024-05-15 2024-03-31 13F ACASTI PHARMA CL A 00430K865 1,882 0 6 0.0000
2024-08-16 2023-12-31 13F/A-1 ACASTI PHARMA CL A 00430K865 1,882 0 0.00 5 0.00 0.0000
2024-02-13 2023-12-31 13F ACASTI PHARMA CL A 00430K865 1,882 0 5 0.0000
2023-11-15 2023-09-30 13F ACASTI PHARMA CL A 00430K865 1,882 -9,413 -83.34 5 0.00 0.0000
2023-08-14 2023-06-30 13F ACASTI PHARMA CL A 00430K873 11,295 0 0.00 6 0.00 0.0000
2023-05-15 2023-03-31 13F ACASTI PHARMA CL A 00430K873 11,295 0 0.00 5 0.00 0.0000
2023-02-14 2022-12-31 13F ACASTI PHARMA CL A 00430K873 11,295 0 0.00 6 -16.67 0.0000
2022-11-14 2022-09-30 13F ACASTI PHARMA CL A 00430K873 11,295 -7,369 -39.48 6 -62.50 0.0000
2022-10-27 2022-06-30 13F/A-1 ACASTI PHARMA CL A 00430K873 18,664 -35,800 -65.73 16 -75.76 0.0000
2022-08-15 2022-06-30 13F ACASTI PHARMA CL A 00430K873 18,664 -35,800 16 0.0000
2022-10-27 2022-03-31 13F/A-1 ACASTI PHARMA CL A 00430K873 54,464 21,133 63.40 66 57.14 0.0000
2022-05-13 2022-03-31 13F ACASTI PHARMA CL A 00430K873 54,464 21,133 66 0.0000
2022-02-14 2021-12-31 13F ACASTI PHARMA CL A 00430K873 33,331 18,582 125.99 42 44.83 0.0000
2021-11-15 2021-09-30 13F ACASTI PHARMA CL A 00430K873 14,749 -164,339 -91.76 29 -71.29 0.0000
2021-08-23 2021-06-30 13F/A-1 ACASTI PHARMA CL A NEW 00430K402 179,088 -199,720 -52.72 101 -55.51 0.0000
2021-08-16 2021-06-30 13F ACASTI PHARMA CL A NEW 00430K402 179,088 -199,720 101 0.0000
2021-05-17 2021-03-31 13F ACASTI PHARMA CL A NEW 00430K402 378,808 340,372 885.56 227 1,646.15 0.0000
2021-02-16 2020-12-31 13F ACASTI PHARMA CL A NEW 00430K402 38,436 364 0.96 13 62.50 0.0000
2020-11-13 2020-09-30 13F ACASTI PHARMA CL A NEW 00430K402 38,072 -29,897 -43.99 8 -75.00 0.0000
2020-08-14 2020-06-30 13F ACASTI PHARMA CL A NEW 00430K402 67,969 -92,816 -57.73 32 -47.54 0.0000
2020-05-26 2020-03-31 13F/A-1 ACASTI PHARMA CL A NEW 00430K402 160,785 -17,654 -9.89 61 -86.04 0.0000
2020-05-15 2020-03-31 13F ACASTI PHARMA CL A NEW 00430K402 160,785 -17,654 61 4.6861
2020-02-14 2019-12-31 13F ACASTI PHARMA CL A NEW 00430K402 178,439 168,169 1,637.48 437 2,200.00 0.0001
2019-11-14 2019-09-30 13F ACASTI PHARMA CL A NEW 00430K402 10,270 -35,417 -77.52 19 -63.46 0.0000
2019-08-14 2019-06-30 13F ACASTI PHARMA CL A NEW 00430K402 45,687 7,789 20.55 52 33.33 0.0000
2019-05-15 2019-03-31 13F ACASTI PHARMA CL A NEW 00430K402 37,898 0 0.00 39 21.88 0.0000
2019-02-14 2018-12-31 13F ACASTI PHARMA CL A NEW 00430K402 37,898 -2,102 -5.25 32 -38.46 0.0000
2019-04-23 2018-09-30 13F/A-2 ACASTI PHARMA CL A NEW 00430K402 40,000 0 0.00 52 126.09 0.0000
2018-11-20 2018-09-30 13F/A-1 ACASTI PHARMA CL A NEW 00430K402 40,000 0 52 0.0000
2018-11-14 2018-09-30 13F ACASTI PHARMA CL A NEW 00430K402 40,000 0 52
2019-04-23 2018-06-30 13F/A-1 ACASTI PHARMA CL A NEW 00430K402 40,000 0 0.00 23 -43.90 0.0000
2018-08-14 2018-06-30 13F ACASTI PHARMA CL A NEW 00430K402 40,000 0 23
2019-04-23 2018-03-31 13F/A-1 ACASTI PHARMA CL A NEW 00430K402 40,000 0 0.00 41 7.89 0.0000
2018-05-14 2018-03-31 13F ACASTI PHARMA CL A NEW 00430K402 40,000 0 41
2019-04-23 2017-12-31 13F/A-1 ACASTI PHARMA CL A NEW 00430K402 40,000 39,300 5,614.29 38 3,700.00 0.0000
2018-02-14 2017-12-31 13F ACASTI PHARMA CL A NEW 00430K402 40,000 39,300 38
2017-11-14 2017-09-30 13F ACASTI PHARMA CL A NEW 00430K402 700 700 1 0.0000
2016-08-12 2016-06-30 13F ACASTI PHARMA CL A NEW 00430K402 0 -15 -100.00 0 -100.00 0.0000
2016-05-12 2016-03-31 13F ACASTI PHARMA CL A NEW 00430K402 15 -3 -16.67 0 0.0000
2016-02-09 2015-12-31 13F ACASTI PHARMA CL A NEW 00430K402 18 18 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.